昂利康(002940.SZ)：获得药品注册证书

Core Viewpoint - The company, Anglikang (002940.SZ), has received a drug registration certificate from the National Medical Products Administration for its drug, Ertugliflozin Metformin Extended-Release Tablets (II), indicating a significant advancement in its product portfolio for diabetes treatment [1] Group 1: Drug Approval Details - The drug is a combination formulation of Ertugliflozin and Metformin Hydrochloride, aimed at improving blood sugar control in adult patients with type 2 diabetes who are already receiving treatment with these medications [1] - The company received the acceptance notice for the drug's marketing authorization application in June 2024 and has recently obtained approval from the National Medical Products Administration [1] - The issuance of the drug registration certificate is considered equivalent to passing the consistency evaluation as per national policy regulations [1]